Liraglutide as add-on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: a 26-week, randomised, double-blind, placebo-controlled trial

被引：0
|
作者：
Rea, R. [1 ]
Blonde, L. [2 ]
Belousova, L. [3 ]
Fainberg, U. [4 ]
Garcia-Hernandez, P. A. [5 ]
Jain, S. M. [6 ]
Kaltoft, M. S. [4 ]
Mosenzon, O. [7 ]
Nafach, J. [8 ]
Palle, M. S. [4 ]
机构：
[1] Univ Fed Parana, Endocrinol & Metab Serv SEMPR, Curitiba, Parana, Brazil
[2] Ochsner Med Ctr, New Orleans, LA USA
[3] Almazov Natl Med Res Ctr, St Petersburg, Russia
[4] Novo Nordisk AS, Soborg, Denmark
[5] Univ Hosp, Serv Endocrinol, Monterrey, Mexico
[6] TOTALL Diabet Hormone Inst, Indore, Madhya Pradesh, India
[7] Hadassah Hebrew Univ Hosp, Jerusalem, Israel
[8] Dubai Hlth Author, Dubai Diabet Ctr, Dubai, U Arab Emirates
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
770
引用
收藏
页码：S371 / S372
页数：2
相关论文
共 50 条
  • [1] Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
    Ludvik, Bernhard
    Frias, Juan P.
    Tinahones, Francisco J.
    Wainstein, Julio
    Jiang, Honghua
    Robertson, Kenneth E.
    Garcia-Perez, Luis-Emilio
    Woodward, D. Bradley
    Milicevic, Zvonko
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05): : 370 - 381
  • [2] Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial
    Blonde, Lawrence
    Belousova, Lidia
    Fainberg, Udi
    Garcia-Hernandez, Pedro A.
    Jain, Sunil M.
    Kaltoft, Margit S.
    Mosenzon, Ofri
    Nafach, Jalal
    Palle, Mads Sundby
    Rea, Rosangela
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (06): : 929 - 937
  • [3] Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial (vol 6, pg 370, 2018)
    Ludvik, B.
    Frias, J. P.
    Tinahones, F. J.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (06): : E5 - E5
  • [4] Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
    Clifford J Bailey
    Jorge L Gross
    Delphine Hennicken
    Nayyar Iqbal
    Traci A Mansfield
    James F List
    [J]. BMC Medicine, 11
  • [5] Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
    Bailey, Clifford J.
    Gross, Jorge L.
    Hennicken, Delphine
    Iqbal, Nayyar
    Mansfield, Traci A.
    List, James F.
    [J]. BMC MEDICINE, 2013, 11
  • [6] A randomised, double-blind, placebo-controlled, 39 week trial of ITCA 650 as add-on therapy in type 2 diabetes
    Baron, M. A.
    Buse, J.
    Azeem, R.
    Kjems, L.
    Rosenstock, J.
    [J]. DIABETOLOGIA, 2015, 58 : S55 - S55
  • [7] Erratum to: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
    Clifford J Bailey
    Jorge L Gross
    Delphine Hennicken
    Nayyar Iqbal
    Traci A Mansfield
    James F List
    [J]. BMC Medicine, 11
  • [8] Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
    Heo, Ji Hye
    Han, Kyung Ah
    Hong, Jun Hwa
    Seo, Hyun-Ae
    Hong, Eun-Gyoung
    Yu, Jae Myung
    Jung, Hye Seung
    Cha, Bong-Soo
    [J]. DIABETES & METABOLISM JOURNAL, 2024, 48 (05)
  • [9] Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Broedl, Uli C.
    Woerle, Hans J.
    [J]. DIABETES CARE, 2014, 37 (06) : 1650 - 1659
  • [10] Once-daily liraglutide vs lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomised controlled clinical trial
    Nauck, M. A.
    Rizzo, M.
    Pirags, V.
    Bosch-Traberg, H.
    Madsen, J.
    Cariou, B.
    [J]. DIABETOLOGIA, 2015, 58 : S37 - S37
12345